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Abstract
Background: Taurolidine (TRD) is a novel agent with multimodal antineoplastic effects. We
present the case of a tumor remission after intravenous administration of taurolidine in a patient
with gastric cancer re-recurrence.
Case presentation: A 58 years old male patient suffering from a gastric adenocarcinoma was
submitted to partial gastrectomy and partial liver resection (pT2, pN1, pM1L (liver segment 2), N0,
V0). 24 months later a local recurrence was diagnosed and the patient was reoperated.
Postoperatively the patient underwent a palliative chemotherapy with eloxatin, FU, and leucovorin.
A subsequent CT-revealed a liver metastasis and a recurrence adjacent to the hepatic artery. After
successful radiofrequency ablation of the liver metastasis the patient was intravenously treated with
2% taurolidine. The patient endured the therapy well and no toxicity was observed. CT-scans
revealed a stable disease without a tumor progression or metastatic spread. After 39 cycles the
patient was submitted to left nephrectomy due to primary urothelial carcinoma and died 2 days
later due to myocardial infarction. Postmortem histology of the esophageal-jejunal anastomosis and
liver revealed complete remission of the known metastasized gastric adenocarcinoma.
Conclusion: The intravenous treatment with 2% taurolidine led to a histological remission of the
tumor growth without any toxicity for the patient.
Background
Surgical resection remains the only treatment modality
offering the possibility of cure for patients with gastric
cancer. Nevertheless, the extent of resection required for
potentially curative operations remains controversial.
Opposite to japanese studies (D3 and D4 lymph node dis-
section) [1], different trials in Europe and USA showed
significantly lower morbidity and mortality rates with no
survival difference when a less radical lymph node dissec-
tion of perigastric- (D1) or regional lymph nodes outside
the perigastric area (D2) was performed [2-4]. So far, adju-
vant chemotherapy in gastric cancer has failed to improve
Published: 24 June 2006
World Journal of Surgical Oncology 2006, 4:34 doi:10.1186/1477-7819-4-34
Received: 28 November 2005
Accepted: 24 June 2006
This article is available from: http://www.wjso.com/content/4/1/34
© 2006 Braumann et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6
(page number not for citation purposes)
World Journal of Surgical Oncology 2006, 4:34 http://www.wjso.com/content/4/1/34survival (e.g. 5-fluorouracil (5-FU) plus high dose meth-
otrexate plus doxorubicin (FAMTX), etoposid plus cispla-
tin (EAP), etoposide plus leucovorin plus 5-FU (ELF), and
epirubicin plus cisplatin plus 5-FU (ECF) [5,6]. In a
locally advanced gastric cancer or in case of relapse the
prognosis is very poor. Therefore, new chemotherapeutic
agents are tested in order to improve survival and the
quality of life.
The antineoplastic substance taurolidine was found to
suppress intraperitoneal gastrointestinal tumor growth
after laparotomy and laparoscopy in animals [6,7]. A sin-
gle intravenous injection of 0,5% taurolidine did not
affect tumor growth in rats [8,9]. Unpublished data
showed a reduction of advanced intraperitoneal neo-
plasm after an intravenous long-term treatment (unpub-
lished). Taurolidine induces apoptosis and inhibited
tumor growth in various cells lines in vitro [10-13]. The
agent was found to decrease the production of Tumor
Necrosis Factor alpha (TNFα) and Interleukin-1β (IL-1β)
in peritoneal macrophages [14] as well as the TNFα and
the VEGF secretion by gastrointestinal neoplasms [15].
Based on these data, a male patient with a gastric cancer
re-relapse was palliatively treated with this agent, under-
going 42 cycles of a 7-days'-intravenously treatment. The
effects on relevant blood parameters, tumor markers, side
effects, and tumor size were analyzed.
Case presentation
A 58-year-old man (83 kilo gram, kg) presented to our
Surgical Department because of a gastric cancer eight years
ago. The past medical history was significant for higher
PSA levels for 10 years without clinical relevance, an acute
myocardial infarction which was treated with coronary
arteries' stenting and an arterial occlusive disease (Fon-
taine IIb). The patient was submitted to surgery and a sub-
total gastrectomy with a gastrojejunostomy and a partial
liver resection were performed (pT2, pN1, pM1L (liver seg-
ment 2), N0, V0). No adjuvant chemotherapy was carried
out.
During the follow-up a local recurrence has been detected
in the abdominal CT-scan 24 months after surgery. The
patient was then submitted to a total gastrectomy with
Roux en Y esophagojejunostomy. A palliative chemother-
apy (eloxatin, 5-fluoruracil, leukovorin) was performed
for 10 months but no remission was observed. Twelve
months later the CT-scan revealed a stable tumor disease
despite chemotherapy adjacent to the hepatic artery. Then
the patient underwent a palliative intravenous therapy
with 2% taurolidine for seven days (per months) with a
daily dose of 300 mg per kg body weight. After twelve
cycles the CT-scan revealed a tumor mass reduction and
the therapy was terminated. Three months later the
patient experienced abdominal discomfort. Diagnostics
showed one liver metastasis in segment 8 which was suc-
cessfully treated with radiofrequency ablation (Figure 2).
The patient was treated with taurolidine monthly ever
since. After the chemotherapy no. 32 an additional pri-
mary urothelial carcinoma in two different sites of the uri-
nary tract (left kidney, urinary bladder) The lesion in the
bladder was localy excized (pTa, G2) while the kidney
lesion was put under observation by the urologists. After
treatment with a total of 39 cycles with taurolidine the
patient was in a good clinical condition and showed no
life quality deficit. At this time the CT-scan (Figure 3)
showed no tumor progression next to the hepatic artery
(stable disease). Four weeks after the completion of the
treatment the patient was admitted to the urology depart-
ment of our hospital in order to be submitted to surgical
treatment of his urothelial carcinoma. A left nephrectomy
was performed. Although there were no intraoperative
problems the patient unexpectedly died of an acute myo-
cardial infarct 48 hours after surgery.
Post mortem histology of the esophageal-jejunal anasto-
mosis and liver revealed surprisingly no signs of the
known adenocarcinoma. We thought this finding was
extremely interesting as we had actually been in front of a
complete remission of his gastrointestinal tumor.
Peripheral leukocyte counts during therapy (values of every fifth cycle is shown)Figur  1
Peripheral leukocyte counts during therapy (values of every 
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The antineoplastic agent taurolidine was intravenously
applied in a 2% solution (Geistlich Pharma AG Wohl-
husen, Switzerland) using a port catheter system. The
monthly therapy (300 mg/kg/day according 24,9 g tauro-
lidine/day) was given for 5 days in four hours' therapy ses-
sions and 2 hours' intervals. Tumor markers (carcino
embryonal antigen-CEA, CA 72-4) were determined at the
beginning and at the end of the therapies. Blood counts
and biochemistry were examined every day. Disease pro-
gression was radiologically followed-up with an abdomi-
nal CT-scan every two months.
Quality of life was assessed using the EORTC QLQ-C30
questionnaire [16], a 30- questionnaire score composed
of multi-item and single-items scales reflecting the quality
of life multidimensionally. It incorporates five functional
scales (physical, role, cognitive, emotional, social), three
symptom scales (fatigue, pain, nausea, vomiting) and a
global health and quality-of life scale. The remaining sin-
gle items evaluate additional symptoms commonly
reported by cancer patients as well as the perceived finan-
cial impact of the disease and treatment.
GCP guidelines and Helsinki declaration for studies on
humans were complied with. The Ethics Committee of the
Charité Campus Mitte, University Hospital, Universitaets-
medizin Berlin, Germany, approved the study design.
Results
The patient tolerated the therapy sessions well. As far as
toxicity is concerned, we have to emphasize on the fact,
that the administered taurolidine concentration (2%) did
not impair the leukopoiesis or the patient's quality of life
(Table 1 and 2). Tumor markers, conjugated bilirubine,
creatinine or urea did not increase. Additionally the agent
infusion is electrolytes-free no other side-effects from tau-
rolidine treatment in the blood parameters were observed.
Low toxicity is a main beneficial feature of taurolidine,
which substantially differentiates the substance from tra-
ditional chemotherapeutic agents, which are quite often
related to devastating toxic complications. According to
standardized clinical and CT-scan criteria with consecu-
tive comparisons of the CT scans during the taurolidine
treatment, we were able to detect no progression of the
tumor growth, so the disease was classified as stable.
Moreover, it could be shown that after radiofrequency
ablation liver tissue regenerates again. It has to be pointed
out, that although consecutive CT-scans showed stable
disease, the post mortem histological examination of the
esophageal-jejunal anastomosis and liver surprisingly
confirmed the absence of any residual disease.
Discussion
The incidence of gastric cancer has decreased worldwide.
Despite this decrease, gastric cancer remains an important
surgical topic, as much as its epidemiology is changing,
thus making therapy for the disease more demanding. At
this time, surgery is the only potentially curative therapy
for this malignancy [2,4,17,18]. The aim of any surgical
approach to gastric carcinoma should be complete resec-
tion with no residual tumor left behind at the end of the
operation (R0 resection). Nevertheless, radical surgery
after relapse is often extremely difficult – or even impossi-
A stable disease of the gastric carcinoma surrounding the hepatic artery (arrow) could be detected after the 36 cycles chemotherapy (clips)Figure 3
A stable disease of the gastric carcinoma surrounding the 
hepatic artery (arrow) could be detected after the 36 cycles 
chemotherapy (clips).
Region of thermoablation, liver segment 8Figure 2
Region of thermoablation, liver segment 8.Page 3 of 6
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A beneficial effect of adjuvant therapy is currently contro-
versial. A meta analysis of 11 published trials including
2096 patients showed no significant benefit for patients
who had adjuvant therapy after R0 resection [19]. Oppo-
site to the western world, several studies clearly favoring
adjuvant therapy in patients with gastric cancer have been
reported from Japan, where adjuvant therapy is consid-
ered a standard modality and is initiated immediately
during the postoperative period or even intraoperatively
[20].
The limited therapy options with traditional chemothera-
peutic substances led to intensive research for new antin-
eoplastic agents. Taurolidine, a synthetic product derived
from the aminosulfone acid taurine, consists of two aro-
matic rings, which are connected with a CH2-group; MW
284. There are several reports in the literature about the
immune modulating and antineoplastic potential of this
substance. Taurolidine reduced the production of TNFα
(2 h contact, IC50 0.5 mM) as well as VEGF (6 h contact,
IC50 1.5 mM), which is a major proangiogenic factor,
might indicate a possible influence on various malignan-
cies [15]. The agent inhibited tumor growth of many enti-
ties with poor responses to current therapeutic regiments
[11,21,22]. Dose-dependent findings are supported by
McCourt et al. [7] and Calabresi et al, [10]. They showed
a four-fold increase of tumor cell necrosis after treatment
with increasing doses in several different malignancies in
vitro. The intravenous application of taurolidine had no
significant side effects at a maximum concentration of
300 mg per kg per day.
We decided to treat our patient with taurolidine because
he did not respond to the standard adjuvant iv chemo-
therapy with eloxatin, 5-fluoruracil, leukovorin. The
patient developed a new local recurrence after successfully
surgical treatment of his first relapse. Under these condi-
tions taurolidine treatment appeared to be a final pallia-
tive option for our patient since traditional therapeutic
modalities failed to control disease progression. In our
palliative intravenous study no side effects were observed.
Table 2: Qualitiy of life score (mean) during intravenous TRD-treatment







Global quality of life 9.0 9.1
Table 1: The intravenous taurolidine treatment did not impair the above mentioned blood parameters after 39 cycles (Wilcoxon test, 
p = not significant).
Serum parameters Median Range
CA 72-4 (tumor marker, U/ml) 0.6 0.3–1.8
CEA (tumor marker, µg/l) 18.8 6.7–32.4
Leukocyte (/µl) 6.4 4.8–13.0
Hemoglobin (g/l) 13.0 10.4–14.8
Hemocrit (%) 40 32–44
Thrombocyte (103/µl) 225 171–321
Glucose (mg/dl) 94 54–283
Saline (mg/dl) 138 130–149
Potassium (mg/dl) 4.3 3.6–5.3
Creatinine (mg/dl) 1.1 0.74–1.75
Urea (mg/dl) 34 22–72
Protein (g/dl) 7.2 6.1–7.4
GOT (U/l) 23 7–95
GPT (U/l) 13 8–73
Total bilirubine (mg/dl) 0.3 0.1–0.6
Alkaline phosphatase (U/l) 70 56–122
Amylase (U/l) 53 44–104
Lipase (U/l) 17.5 17–18
INR 1.1 1.0–1.2Page 4 of 6
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the chemotherapy was terminated following the patient's
wish. After a successfully radiofrequency ablation of one
liver metastasis (S8) the taurolidine therapy was initiated
again leading to a radiological (CT) stable disease. The
patient died due to a postoperative complication after
urological surgery, but post mortem histology of
esophago-jejunal anastomosis and liver revealed no
tumor at all. This finding was a really surprising one as it
seems that taurolidine had caused a complete remission
of the gastointestinal tumor (gastric cancer). This result
could be only poorly expected with the conventional
chemotherapy. There are literature reports that the agent
might be effective in the treatment of other tumors as well.
Taurolidine seems to have a multimodal efficacy on dif-
ferent malignancies both in human as well as in animal
models. Stendel et al, noticed a partial remission of gliob-
lastoma in two patients [23] which were treated with 20 g
taurolidine per day. The substance has been found to exert
a direct and selective effect on glial and neuronal brain
tumor cells via presently unknown apoptotic pathways
[13]. The suppression of tumor growth could be also
explained by intracellular effects causing apoptosis [24]
presumably by a mitochondria cytochrome c-dependent
apoptotic mechanism [11], reduction of the TNFα and
VEGF production on malignant tumor cells [25]. Moreo-
ver, recently the suppression of protein biosynthesis was
found to lead to cell death in malignancies (IC50 approx-
imately 1.4 mM) [15]. For example for abdominal lavage
0.5% taurolidine corresponding to approximately 16 mM
are used for short time periods such as 2 hours in our
clinic. The current patient received a weight-adjusted treat-
ment (reaching up to 1.6 mM blood concentration) oppo-
site to the glioblastoma patients (20 g each) whose
therapy was successful. On the contrary, urothelial carci-
noma was not affected. These findings might suggest that
concentrations used exert dissimilar antineoplastic effects
on different entities. The specific anti-tumor conse-
quences have been assessed to purge tumor cells from chi-
meric mixtures of bone marrow resulting in a selective
and complete elimination of viable cancer cells [26]. Tau-
rolidine has been described to have immune modulating
effects [24]. Therefore, peripheral leukocyte counts were
analyzed to determine leukopenia which is a common
side effect of other chemotherapeutic agents. In the cur-
rent case leukopoesis and thrombopoesis, which occurs in
the bone marrow, were not impaired. This fact should be
considered as a major advantage of this agent compared
to the devastating cytotoxic effects of conventional chem-
otherapeutics and it might implicate that the intravenous
use might be safe even in immune suppressed patients in
advanced tumor stages. Moreover, these findings will
become more evident by using higher concentrations for
other malignant entities. It is obvious that toxicity can not
be assessed only in one patient. A new phase III clinical
study about influence of taurolidine on gastrointestinal
tumor recurrences in over 25 patients is currently being
conducted in our Department. Results are expected with
great interest, but first unpublished data show a favorable
outcome as far as toxicity is concerned.
Taking the current findings together, the antineoplastic
efficacy seems to be a mixture of the mentioned mecha-
nisms. The intravenous 5-day-therapy of 2% taurolidine is
safe and anti-tumorigenic in the advanced gastric cancer.
On the contrary, urothelial carcinoma was not affected. A
clinical phase clinical III study has been set up to evaluate
the benefit of the intravenous efficacy on progressive
tumor growth. The results are expected with great interest.
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